Skip to main content
PMC home page
American Journal of Alzheimer's Disease and Other Dementias logoLink to American Journal of Alzheimer's Disease and Other Dementias
. 2008 Dec;23(6):571–585. doi: 10.1177/1533317508325093

Efficacy of a Vitamin/Nutriceutical Formulation for Early-stage Alzheimer's Disease: A 1-year, Open-label Pilot Study With an 16-Month Caregiver Extension

Amy Chan 1, James Paskavitz 2, Ruth Remington 3, Shelly Rasmussen 4, Thomas B Shea 5
PMCID: PMC10846284  PMID: 19047474

Abstract

We examined the efficacy of a vitamin/nutriceutical formulation (folate, vitamin B6, alpha-tocopherol, S-adenosyl methionine, N-acetyl cysteine, and acetyl-L-carnitine) in a 12-month, open-label trial with 14 community-dwelling individuals with early-stage Alzheimer's disease. Participants improved in the Dementia Rating Scale and Clock-drawing tests (Clox 1 and 2). Family caregivers reported improvement in multiple domains of the Neuropsychiatric Inventory (NPI) and maintenance of performance in the Alzheimer's Disease Cooperative Study—Activities of Daily Living (ADL). Sustained performance was reported by caregivers for those participants who continued in an 16-month extension. Performance on the NPI was equivalent to published findings at 3 to 6 months for donepezil and exceeded that of galantamine and their historical placebos. Participants demonstrated superior performance for more than 12 months in NPI and ADL versus those receiving naproxen and rofecoxib or their placebo group. This formulation holds promise for treatment of early-stage Alzheimer's disease prior to and/or as a supplement for pharmacological approaches. A larger, placebo-controlled trial is warranted.

Keywords: cognition, behavioral response, vitamin, nutriceutical, supplement

Full Text

The Full Text of this article is available as a PDF (770.6 KB).

Contributor Information

Amy Chan, Center for Cell Neurobiology and Neurodegeneration Research, University of Massachusetts Lowell, MA.

James Paskavitz, Perceptive Informatics, Inc, Waltham, MA.

Ruth Remington, Center for Cell Neurobiology and Neurodegeneration Research, University of Massachusetts Lowell, MA.

Shelly Rasmussen, Department of Mathematics, University of Massachusetts Lowell, MA.

Thomas B. Shea, Center for Cell Neurobiology and Neurodegeneration Research, University of Massachusetts Lowell, MA Thomas_Shea@uml.edu .

References

  1. Swerdlow RH Pathogenesis of Alzheimer's disease. Clin Interv Aging. 2007;2:347-359. [PMC free article] [PubMed] [Google Scholar]
  2. Shah S., Reichman WE Treatment of Alzheimer's disease across the spectrum of severity. Clin Interv Aging. 2006;1: 131-142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Burns A., Gauthier S., Perdomo C. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2007;22:806-812. [DOI] [PubMed] [Google Scholar]
  4. Feldman HH, Schmitt FA, Olin JT; Memantine MEM-MD-02 Study Group. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment . Alzheimer Dis Assoc Disord. 2006;20:263-268. [DOI] [PubMed] [Google Scholar]
  5. Johannsen P. Medical treatment of Alzheimer's disease. Ugeskr Laeger. 2006;168:3424-3429. [PubMed] [Google Scholar]
  6. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., Mobius HJ A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol. 2006;63:49-54. [DOI] [PubMed] [Google Scholar]
  7. Seow D., Gauthier S. Pharmacotherapy of Alzheimer disease. Can J Psychiatry. 2007;52:620-629. [DOI] [PubMed] [Google Scholar]
  8. McGeer PL , Schulzer M., McGeer EG Arthritis and antiinflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies. Neurology. 1996;47:425-432. [DOI] [PubMed] [Google Scholar]
  9. Beier MT Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention. Pharmacotherapy. 2007;27:399-411. [DOI] [PubMed] [Google Scholar]
  10. Park KW, Pavlik VN, Rountree SD, Darby EJ, Doody RS Is functional decline necessary for a diagnosis of Alzheimer's disease? Dement Geriatr Cogn Disord. 2007;24: 375-379. [DOI] [PubMed] [Google Scholar]
  11. Touchon J., Portet F., Gauthier S. Prevention trials in Alzheimer disease: one step forward? Neurology. 2006;67(9 suppl 3):S21-S22. [DOI] [PubMed] [Google Scholar]
  12. Fusco D., Colloca G., Lo Monaco MR, Cesari M. Effects of antioxidant supplementation on the aging process. Clin Interv Aging. 2007;2:377-387. [PMC free article] [PubMed] [Google Scholar]
  13. Mattson MM, Shea TB Folate and homocysteine in neural plasticity and neurodegenerative disorders . Trends Neurosci. 2002;26:137-146. [DOI] [PubMed] [Google Scholar]
  14. Burgener SC , Buettner L., Coen Buckwlater K., et al. Evidence supporting nutritional interventions for persons in early-stage Alzheimer's disease. J Nutr Health Aging. 2008;12:18-21. [DOI] [PubMed] [Google Scholar]
  15. Panza F., Solfrizzi V., Colacicco AM, et al. Mediterranean diet and cognitive decline. Public Health Nutr. 2004;7: 959-963. [DOI] [PubMed] [Google Scholar]
  16. Zhu X., Su B., Wang X., Smith MA, Perry G. Causes of oxidative stress in Alzheimer disease. Cell Mol Life Sci. 2007;64:2202-2210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Joseph JA, Denisova NA, Bielinski D., Fisher DR, Shukitt-Hale. Oxidative stress protection and vulnerability in aging: putative nutritional implications for intervention. Mech Ageing Dev . 2000;116:141-153. [DOI] [PubMed] [Google Scholar]
  18. Berman K., Brodaty H. Tocopherol (vitamin E) in Alzheimer's disease and other neurodegenerative disorders. CNS Drugs. 2004;18:807-825. [DOI] [PubMed] [Google Scholar]
  19. Esposito E.,Rotilio D.,DiMatteo V.,DiGuilio C.,Cacchio M., Algeri S. A reiew of specific dietary antioxidants and the effects on biochemical mechanisms related to neurodegenerative processes. Neurobiol Aging. 2002;23:719-735. [DOI] [PubMed] [Google Scholar]
  20. Morris MC, Evans DA, Tangey CC, Bienas JL, Wilson RS, Aggarwal NT Relation of the tocopherol forms to incident Alzheimer's disease and to cognitive change. Am J Clin Nutr. 2005;82:508-514. [DOI] [PubMed] [Google Scholar]
  21. Dhitavat S. , Rivera E., Shea TB Differential efficacy of lipophilic and cytosolic antioxidants on generation of reactive oxygen species by amyloid-beta. J Alz Dis. 2001;3:525-529. [PubMed] [Google Scholar]
  22. Liu H., Wang H., Shenvi S., Hagen TM, Liu RM Glutathione metabolism during aging and in Alzheimer disease. Ann N Y Acad Sci. 2004;1019:346-349. [DOI] [PubMed] [Google Scholar]
  23. Lovell MA, Xie C., Markesbery WR Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology. 1998;51:1562-1566. [DOI] [PubMed] [Google Scholar]
  24. Bernardini S., Bellincampi L., Ballerini S., et al. Glutathione S-transferase P1 *C allelic variant increases susceptibility for late-onset Alzheimer disease: association study and relationship with apolipoprotein E epsilon4 allele. Clin Chem. 2005;51:944-951. [DOI] [PubMed] [Google Scholar]
  25. Spalletta G. , Bernardini S., Bellincampi L., et al. Glutathione S-transferase P1 and T1 gene polymorphisms predict longitudinal course and age at onset of Alzheimer disease. Am J Geriatr Psychiatry. 2007;15: 879-887. [DOI] [PubMed] [Google Scholar]
  26. Adair JC, Knoefel JE, Morgan N. Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology. 2001;57:1515-1517. [DOI] [PubMed] [Google Scholar]
  27. St George-Hyslop PH Genetic factors in the genesis of Alzheimer's disease. Ann N Y Acad Sci. 2000;924:1-7. [DOI] [PubMed] [Google Scholar]
  28. Reyes-EngelA, Munoz E., Gaitan MJ, et al. Implications on human fertility of the 677C->T and 1298A->C polymorphisms of the MTHFR gene: consequences of a possible genetic selection . Mol Hum Reprod. 2002;8:952-957. [DOI] [PubMed] [Google Scholar]
  29. Tchantchou F., Graves M., Ortiz D., Shea TB S-adenosyl methionine: a link between nutritional and genetic risk factors in Alzheimer's disease. J Nutri Health Aging. 2006;10:541-544. [PubMed] [Google Scholar]
  30. Connelly PJ , Prentice NP, Cousland G., Bonham J. A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease. Int J Geriatr Psychiatry. 2008;23: 155-160. [DOI] [PubMed] [Google Scholar]
  31. Ellinson M. , Thomas J., Patterson A. A critical evaluation of the relationship between serum vitamin B12, folate and total homocystein with cognitive impairment in the elderly. J Hum Nutr Diet. 2004;17:371-383. [DOI] [PubMed] [Google Scholar]
  32. Salerno-Kennedy R., Cashman KD Relationship between dementia and nutrition-related factors and disorders: an overview. Int J Vitam Nutr Res. 2005;75:83-95. [DOI] [PubMed] [Google Scholar]
  33. Luchsinger JA, Noble JM, Scarmeas N. Diet and Alzheimer's disease. Curr Neurol Neurosci Rep. 2007;7: 366-372. [DOI] [PubMed] [Google Scholar]
  34. Malouf R., Grimley Evans J. The effect of vitamin B6 on cognition. Cochrane Database Syst Rev. 2003;(4): CD004393. [DOI] [PubMed] [Google Scholar]
  35. Malouf M., Grimley EJ, Areosa SA Folic acid with or without vitamin B12 for cognition and dementia. Cochrane Database Syst Rev. 2003;(4):CD004514. [DOI] [PubMed] [Google Scholar]
  36. Kennedy BP, Bottiglieri T., Arning E., Ziegler MG, Hansen LA, Masliah E. Elevated S-adenosylhomocysteine in Alzheimer brain: influence on methyltransferases and cognitive function. J Neural Transm. 2004. ;111:547-567. [DOI] [PubMed] [Google Scholar]
  37. Tchantchou F. , Graves M., Ashline D., et al. Increased transcription and activity of glutathione synthase in response to deficiencies in folate, vitamin E and apolipoprotein E. J Neurosci Res. 2004;75:508-515. [DOI] [PubMed] [Google Scholar]
  38. Fuso A., Seminara L., Cavallaro RA, D'Anselmi F., Scarpa S. S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production . Mol Cell Neurosci. 2005;28:195-204. [DOI] [PubMed] [Google Scholar]
  39. Scarpa S., Fuso A., D'Anselmi F., Cavallaro RA Presenilin 1 gene silencing by S-adenosylmethionine: a treatment for Alzheimer disease? FEBS Lett. 2003;541:145-148. [DOI] [PubMed] [Google Scholar]
  40. Bottiglieri T. S-Adenosyl-L-methionine (SAMe): from the bench to the bedside-molecular basis of a pleiotrophic molecule. Am J Clin Nutr. 2002;76: 1151S-1157S. [DOI] [PubMed] [Google Scholar]
  41. Di Rocco A. , Rogers JD, Brown R., Werner P., Bottiglieri T. S-adenosyl-methionine improves depression in patients with Parkinson's disease in an open-label clinical trial. Mov Disord. 2000;15:1225-1229. [DOI] [PubMed] [Google Scholar]
  42. Mischoulon D., Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr. 2002;76:1158S-1161S. [DOI] [PubMed] [Google Scholar]
  43. Aureli T., Puccetti C., Di Cocco ME, et al. Entry of [(1,2-13C2) acetyl]-L-carnitine in liver tricarboxylic acid cycle and lipogenesis: a study by 13C NMR spectroscopy in conscious, freely moving rats. Eur J Biochem. 1999;263:287-293. [DOI] [PubMed] [Google Scholar]
  44. Thaj LJ, Carta A., Clarke WR, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology. 1996;47: 705-711. [DOI] [PubMed] [Google Scholar]
  45. Barnes CA, Markowska AL, Ingram DK, et al. Acetyl-1-carnitine. 2: Effects on learning and memory performance of aged rats in simple and complex mazes. Neurobiol Aging. 1990;11:499-506. [DOI] [PubMed] [Google Scholar]
  46. Chan A., Shea TB Dietary and genetically-induced oxidative stress alter tau phosphorylation: influence of folate and apolipoprotein E deficiency. J Alzheimers Dis. 2006;9:399-405. [DOI] [PubMed] [Google Scholar]
  47. Chan A., Shea TB Folate deprivation increases presenilin expression, gamma-secretase activity and Abeta levels in murine brain: potentiation by Apoe deficiency and alleviation by dietary S-adenosyl methionine. J Neurochem. 2007;102:753-760. [DOI] [PubMed] [Google Scholar]
  48. Chan A., Tchantchou F., Graves V., Rozen R., Shea TB Dietary and genetic compromise in folate availability reduces acetylcholine and cognitive performance: critical role of S-adenosylmethionine. J Health Nutr Aging. 2008;12:252-261. [DOI] [PubMed] [Google Scholar]
  49. De La Cruz JP, Pavia J., Gonzalez-Correa JA, Ortiz P., Sanchez de la Cuesta F. Effects of chronic administration of S-adenosyl-L-methionine on brain oxidative stress in rats. Naunyn Schmiedebergs Arch Pharmacol. 2000;361:47-52. [DOI] [PubMed] [Google Scholar]
  50. De La Cruz JP, Villalobos MA, Cuerda MA, Guerrero A., González-Correa JA, Sánchez D.e La Cuesta F. Effects of S-adenosyl-L-methionine on lipid peroxidation and glutathione levels in rat brain slices exposed to reoxygenation after oxygen-glucose deprivation. Neurosci Lett. 2002;318:103-107. [DOI] [PubMed] [Google Scholar]
  51. Dhitavat S. , Ortiz D., Rogers E., Rivera E., Shea TB Folate, vitamin E and acetyl-L-carnitine provide synergistic protection against oxidative stress resulting from exposure of human neuroblastoma cells to amyloid beta. Brain Res. 2005;9:114-117. [DOI] [PubMed] [Google Scholar]
  52. Fu AL, Dong ZH, Sun MJ Protective effect of N-acetyl-L-cysteine on amyloid beta-peptide-induced learning and memory deficits in mice. Brain Res. 2006. ;1109: 201-206. [DOI] [PubMed] [Google Scholar]
  53. Markowska AL , Olton DS Dietary acetyl-L-carnitine improves spatial behaviour of old rats. Int J Clin Pharmacol Res. 1990;10:65-68. [PubMed] [Google Scholar]
  54. Shea TB, Chan A. S-adenosyl methionine: a natural therapeutic agent effective against multiple hallmarks and risk factors associated with Alzheimer's disease. J Alzheimers Dis. 2008;13:67-70. [DOI] [PubMed] [Google Scholar]
  55. Shea TB, Ortiz D., Rogers E. Differential susceptibity of transgenic mice lacking one or both apolipoprotein alleles to folate and vitamin E deprivation. J Alzheimers. Dis. 2004;6:269-273. [DOI] [PubMed] [Google Scholar]
  56. Tchantchou F., Graves M., Rogers E., Ortiz D., Shea TB N-acetyl cysteine alleviates neurodegeneration and increased glutathione expression in normal and ApoEdeficient mice. J Alzheimers Dis. 2005;7:135-138. [DOI] [PubMed] [Google Scholar]
  57. Tchantchou F., Graves M., Rogers E., Ortiz D., Shea TB Dietary supplementation with 3-deaza adenosine, N-acetyl cysteine and S-adenosyl methionine provide neuroprotection against multiple consequences of vitamin deficiency and oxidative challenge: relevance to age-related neurodegeneration. Neuromol Med. 2005;6: 93-104. [DOI] [PubMed] [Google Scholar]
  58. Villalobos MA, De La Cruz JP, Cuerda MA, Ortiz P., Smith-Agreda JM, Sanchez De La Cuesta F. Effect of S-adenosyl-L-methionine on rat brain oxidative stress damage in a combined model of permanent focal ischemia and global ischemia-reperfusion . Brain Res. 2000;883:31-40. [DOI] [PubMed] [Google Scholar]
  59. Chan A., Shea TB Improved cognitive performance and decreased aggression in normal and ApoE4 mice following dietary supplementation with N-acetyl cysteine, acetyl-L-carnitine and S-adenosyl methionine. Neuromol Med. 2007. ;9:264-269. [DOI] [PubMed] [Google Scholar]
  60. Shea TB, Rogers E. Folate quenches oxidative damage in brains of apolipoprotein E-deficient mice: augmentation by vitamin E. Brain Res Mol Brain Res. 2002;108:1-6. [DOI] [PubMed] [Google Scholar]
  61. Mckhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan EM Clinical diagnosis of Alzheimer's disease report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984. ;34:939-944. [DOI] [PubMed] [Google Scholar]
  62. Lucas JA, Ivnik RJ, Smith GE, et al. Normative data for the Mattis Dementia Rating Scale. J Clin Exp Neuropsychol. 1993;20:536-547. [DOI] [PubMed] [Google Scholar]
  63. Monsch AU, Bondi MW, Salmon DP, et al. Clinical validity of the Mattis Dementia Rating Scale in detecting Dementia of the Alzheimer type. A double cross-validation and application to a community-dwelling sample. Arch Neurol. 1995;52:899-904. [DOI] [PubMed] [Google Scholar]
  64. Royall DR, Cordes JA, Polk M. CLOX: an executive clock drawing test. J Neurol Neurosurg Psychiatry. 1998;64: 588-594. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Paskavitz JF , Gunstad JJ, Samuel JE Clock drawing and frontal lobe behavioral effects of memantine in Alzheimer's disease: a rater-blinded study. Am J Alzheimers Dis Other Demen. 2006;21:454-459. [DOI] [PubMed] [Google Scholar]
  66. Cummings JL The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48:S10-S16. [DOI] [PubMed] [Google Scholar]
  67. Galasko D., Bennett D., Sano M., et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2): S33-S39. [PubMed] [Google Scholar]
  68. Potkin SG The ABC of Alzheimer's disease: ADL and improving day-to-day functioning of patients. Int Psycho-geriatr. 2002;14(suppl 1):7-26. [DOI] [PubMed] [Google Scholar]
  69. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum; 1988. [Google Scholar]
  70. Erkinjuntti T., Kurz A., Gauthier S., Bullock R., Lilienfeld S., Damaraju CV Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359:1283-1290. [DOI] [PubMed] [Google Scholar]
  71. Feldman H., Gauthier S., Hecker J., Vellas B., Subbiah P., Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001;57:613-620. [DOI] [PubMed] [Google Scholar]
  72. Aisen PS, Schafer KA, Grundman M., et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289:2819-2826. [DOI] [PubMed] [Google Scholar]
  73. Bouchard RW, Rossor M. Typical clinical features. Clinical Diagnosis and Management of Alzheimer's Disease. In: Gauthier S, ed. London: Martin Dunitz Ltd; 1996: 35-51. [Google Scholar]
  74. Conn D., Thorpe L. Assessment of behavioural and psychological symptoms associated with dementia . Can J Neurol Sci. 2007;34(suppl 1):S67-S71. [DOI] [PubMed] [Google Scholar]
  75. Craig D., Mirakhur A., Hart DJ, McIlroy SP, Passmore AP A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease. Am J Geriatr Psychiatry. 2005;13:460-468. [DOI] [PubMed] [Google Scholar]
  76. Hinchcliffe AC, Hyman IL, Blizard B., Livingston G. Behavioural complications of dementia-can they be treated? Int J Geriatr Psychiatry. 1995;10:839-847. [Google Scholar]
  77. Matsumoto N. , Ikeda M., Fukuhara R., et al. Caregiver burden associated with behavioral and psychological symptoms of dementia in elderly people in the local community . Dement Geriatr Cogn Disord. 2007;23: 219-224. [DOI] [PubMed] [Google Scholar]
  78. de Vugt ME, Riedijk SR, Aalten P., Tibben A., van Swieten JC, Verhey FR Impact of behavioural problems on spousal caregivers: a comparison between Alzheimer's disease and frontotemporal dementia. Dement Geriatr Cogn Disord. 2006;22:35-41. [DOI] [PubMed] [Google Scholar]
  79. Sachs GS A review of agitation in mental illness: burden of illness and underlying pathology. J Clin Psychiatry. 2006;67(suppl 10):5-12. [PubMed] [Google Scholar]
  80. Shin IS, Carter M., Masterman D., Fairbanks L., Cummings JL Neuropsychiatric symptoms and quality of life in Alzheimer disease. Am J Geriatr Psychiatry. 2005;13:469-474. [DOI] [PubMed] [Google Scholar]
  81. Paton J., Johnston K., Katona C., Livingston G. What causes problems in Alzheimer's disease: attributions by caregivers. A qualitative study. Int J Geriatr Psychiatry. 2004;19:527-532. [DOI] [PubMed] [Google Scholar]
  82. Riello R., Geroldi C., Zanetti O., Frisoni GB Caregiver's distress is associated with delusions in Alzheimer's patients . Behav Med. 2002;28:92-98. [DOI] [PubMed] [Google Scholar]
  83. Buhr GT, White HK Difficult behaviors in long-term care patients with dementia. J Am Med Dir Assoc. 2007;8(3 suppl 2):e101-e113. [DOI] [PubMed] [Google Scholar]
  84. Sourial R., McCusker J., Cole M., Abrahamowicz M. Agitation in demented patients in an acute care hospital: prevalence, disruptiveness, and staff burden. Int Psycho-geriatr. 2001. ;13:183-197. [DOI] [PubMed] [Google Scholar]
  85. Aalten P., Verhey FR, Boziki M., et al. Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part II. Dement Geriatr Cogn Disord. 2008;25:1-8. [DOI] [PubMed] [Google Scholar]
  86. de Vugt ME, Riedijk SR, Aalten P., Tibben A., van Swieten JC, Verhey FR Impact of behavioural problems on spousal caregivers: a comparison between Alzheimer's disease and frontotemporal dementia. Dement Geriatr Cogn Disord. 2006;22:35-41. [DOI] [PubMed] [Google Scholar]
  87. Cummings JL , Schneider L., Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry. 2004;161:532-538. [DOI] [PubMed] [Google Scholar]
  88. De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial . Clin Ther. 2003;25:178-193. [DOI] [PubMed] [Google Scholar]
  89. Sun Y., Lu CJ, Chien KL, Chen ST, Chen RC Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients. Clin Ther. 2007;29: 2204-2214. [DOI] [PubMed] [Google Scholar]
  90. Connelly PJ, Prentice NP, Cousland G., Bonham J. A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease. Int J Geriatr Psychiatry. 2008;23:155-160. [DOI] [PubMed] [Google Scholar]
  91. Hager K., Kenklies M., McAfoose J., Engel J., Munch G. Alpha-lipoic acid as a new treatment option for Alzheimer's disease-a 48 months follow-up analysis. J Neural Transm Suppl. 2007;(72):189-193. [DOI] [PubMed] [Google Scholar]
  92. Chan A., Paskvitz J., Shea TB A novel vitamin/nutriceutical formulation that delays cognitive decline and improves mood in early-stage Alzheimer's disease. Alzheimer's Dement. 2007;3:S98. [Google Scholar]

Articles from American Journal of Alzheimer's Disease and Other Dementias are provided here courtesy of SAGE Publications

RESOURCES